Letter

More on albumin

BMJ 1999; 318 doi: 10.1136/bmj.318.7192.1214b (Published 1 May 1999)
Cite this as: BMJ 1999;318:1214.3

Access to the full text of this article requires a subscription or payment. Please log in or subscribe below.

Use of human albumin in UK fell substantially when systematic review was published

  1. Ian Roberts, Director (Ian.Roberts@ich.ucl.ac.uk),
  2. Philip Edwards, Data manager,
  3. Brian McLelland, Director
  1. Child Health Monitoring Unit, Department of Epidemiology and Public Health, Institute of Child Health, London WC1N 1EH
  2. Scottish National Blood Transfusion Service, Headquarters Unit, Edinburgh EH17 7QT
  3. Department of Burns and Plastic Surgery, Royal Victoria Hospital, Belfast BT12 6BA

    EDITOR—After publication of the Cochrane Injuries Group Albumin Reviewers' systematic review of albumin administration in critically ill patients1 the Committee on Safety of Medicines convened an expert working party to consider the implications for the use of albumin in the United Kingdom. To date the committee has not made any announcement. The results of the review were widely reported in the medical and lay press,2 and this may have influenced the use of albumin.

    We requested data on the monthly issues of albumin solutions to regional blood centres and hospitals between 1993 and 1999 from the Bio Products Laboratory (which serves England and Wales) and the Protein Fractionation Centre of the Scottish National Blood Transfusion Service (which serves Scotland and Northern Ireland). Issues were expressed in kg of albumin, reflecting the total albumin content of the various dose units. A …

    Access to the full text of this article requires a subscription or payment

    Subscribe

    Article access

    Article access for 1 day

    Purchase this article for £20 $30 €32*

    The PDF version can be downloaded as your personal record

    * Prices do not include VAT

    Rapid responses

    THIS WEEK'S POLL

    BMJ most popular